|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Systematic review of colorectal cancer screening guidelines for average-risk adults: Summarizing the current global recommendations显示文摘AIM To summarize and compare worldwide colorectal cancer(CRC) screening recommendations in order to identify similarities and disparities.METHODS A systematic literature search was performed using MEDLINE, EMBASE, Scopus, CENTRAL and ISI Web of knowledge identifying all average-risk CRC screening guideline publications within the last ten years and/or position statements published in the last 2 years. In addition, a hand-search of the webpages of National Gastroenterology Society websites, the National Guideline Clearinghouse, the BMJ Clinical Evidence website,Google and Google Scholar was performed. RESULTS Fifteen guidelines were identified. Six guidelines were published in North America, four in Europe, four in Asia and one from the World Gastroenterology Organization. The majority of guidelines recommend screening average-risk individuals between ages 50 and 75 using colonoscopy(every 10 years), or flexible sigmoidoscopy(FS, every 5 years) or fecal occult blood test(FOBT, mainly the Fecal Immunochemical Test, annually or biennially). Disparities throughout the different guidelines are found relating to the use of colonoscopy, rank order between test, screening intervals and optimal age ranges for screening. CONCLUSION Average risk individuals between 50 and 75 years should undergo CRC screening. Recommendations for optimal surveillance intervals, preferred tests/test cascade as well as the optimal timing when to start and stop screening differ regionally and should be considered for clinical decision making. Furthermore, local resource availability and patient preferences are important to increase CRC screening uptake, as any screening is better than none. | Florence Bénard Alan N Barkun Myriam Martel Daniel von Renteln | 2018 | World Journal of Gastroenterology2018，24，1： | 16 |
| 2 | Systematic review and meta-analysis of colon cleansing preparations in patients with inflammatory bowel disease显示文摘AIM To performed a systematic review and meta-analysis to determine any possible differences in terms of effectiveness, safety and tolerability between existing colon-cleansing products in patients with inflammatory bowel disease.METHODS Systematic searches were performed( January 1980-September 2016) using MEDLINE, EMBASE, Scopus, CENTRAL and ISI Web of knowledge for randomized trials assessing preparations with or without adjuvants, given in split and non-split dosing, and in high(> 3 L) or low-volume(2 L or less) regimens. Bowel cleansing quality was the primary outcome. Secondary outcomes included patient willingness-torepeat the procedure and side effects/complications.RESULTS Out of 439 citations, 4 trials fulfilled our inclusion criteria(n = 449 patients). One trial assessed the impact of adding simethicone to polyethylene glycol(PEG) 4 L with no effect on bowel cleansing quality, but a better tolerance. Another trial compared senna to castor oil, again without any differences in term of bowel cleansing. Two trials compared the efficacy of PEG high-volume vs PEG low-volume associated to an adjuvant in split-dose regimens: PEG low-dose efficacy was not different to PEG high-dose; OR = 0.84(0.37-1.92). A higher proportion of patients were willing to repeat low-volume preparations vs high-volume; OR = 5.11(1.31-20.0). CONCLUSION In inflammatory bowel disease population, PEG lowvolume regimen seems not inferior to PEG high-volume to clean the colon, and yields improved willingness-torepeat. Further additional research is urgently required to compare contemporary products in this population. | Sophie Restellini Omar Kherad Talat Bessissow Charles Ménard Myriam Martel Maryam Taheri Tanjani Peter L Lakatos Alan N Barkun | 2017 | World Journal of Gastroenterology2017，23，32： | 16 |
| 3 | Validation of the Rockall scoring system for outcomes from non-variceal upper gastrointestinal bleeding in a Canadian setting显示文摘AIM: To validate the Rockall scoring system for predicting outcomes of rebleeding, and the need for a surgical procedure and death. METHODS: We used data extracted from the Registry of Upper Gastrointestinal Bleeding and Endoscopy including information of 1869 patients with non-variceal upper gastrointestinal bleeding treated in Canadian hospitals. Risk scores were calculated and used to classify patients based on outcomes. For each outcome, we used χ2 goodness-of-fit tests to assess the degree of calibration, and built receiver operating characteristic curves and calculated the area under the curve (AUC) to evaluate the discriminative ability of the scoring system. RESULTS: For rebleeding, the χ2 goodness-of-fit test indicated an acceptable fit for the model [χ2 (8) = 12.83, P = 0.12]. For surgical procedures [χ2 (8) = 5.3, P = 0.73] and death [χ2 (8) = 3.78, P = 0.88], the tests showed solid correspondence between observed proportions and predicted probabilities. The AUC was 0.59 (95% CI: 0.55-0.62) for the outcome of rebleeding and 0.60 (95% CI: 0.54-0.67) for surgical procedures, representing apoor discriminative ability of the scoring system. For the outcome of death, the AUC was 0.73 (95% CI: 0.69-0.78), indicating an acceptable discriminative ability. CONCLUSION: The Rockall scoring system provides an acceptable tool to predict death, but performs poorly for endpoints of rebleeding and surgical procedures. | Robert A Enns Yves M Gagnon Alan N Barkun David Armstrong Jamie C Gregor Richard N Fedorak RUGBE Investigators Group | 2006 | World Journal of Gastroenterology2006，12，48： | 14 |
| 4 | Randomized trial in malignant biliary obstruction:Plastic vs partially covered metal stents显示文摘AIM:To compare efficacy and complications of par-tially covered self-expandable metal stent(pcSEMS)to plastic stent(PS)in patients treated for malignant,infrahilar biliary obstruction.METHODS:Multicenter prospective randomized clinical trial with treatment allocation to a pcWallstent(SEMS)or a 10 French PS.Palliative patients aged≥18,for infrahilar malignant biliary obstruction and a Karnofsky performance scale index>60%from 6 participating North American university centers.Primary endpoint was time to stent failure,with secondary outcomes of death,adverse events,Karnofsky performance score and short-form-36 scale administered on a three-monthly basis for up to 2 years.Survival analyses were performed for stent failure and death,with Cox proportional hazards regression models to determine significant predictive characteristics.RESULTS:Eighty-five patients were accrued over 37mo,42 were randomized to the SEMS group and 83patients were available for analyses.Time to stent failure was 385.3±52.5 d in the SEMS and 153.3±19.8 d in the PS group,P=0.006.Time to death did not differ between groups(192.3±23.4 d for SEMS vs211.5±28.0 d for PS,P=0.70).The only significant predictor was treatment allocation,relating to the time to stent failure(P=0.01).Amongst other measured outcomes,only cholangitis differed,being more common in the PS group(4.9%vs 24.5%,P=0.029).The small number of patients in follow-up limits longitudinal assessments of performance and quality of life.From an initially planned 120 patients,only 85 patients were recruited.CONCLUSION:Partially covered SEMS result in a longer duration till stent failure without increased complication rates,yet without accompanying measurable benefits in survival,performance,or quality of life. | Peter L Moses Khalid M AlNaamani Alan N Barkun Stuart R Gordon Roger D Mitty M Stanley Branch Thomas E Kowalski Myriam Martel Viviane Adam | 2013 | World Journal of Gastroenterology2013，19，46： | 6 |
| 5 | The Clavien-Dindo Classification of Surgical Complications: Five-Year Experience显示文摘 | Pierre A. Clavien Jeffrey Barkun Michelle L. de Oliveira Jean Nicolas Vauthey Daniel Dindo Richard D. Schulick Eduardo de Santiba?es Juan Pekolj Ksenija Slankamenac Claudio Bassi Rolf Graf René Vonlanthen Robert Padbury John L. Cameron Masatoshi Makuuchi | 2009 | Annals of Surgery2009，，2： | 4 |
| 6 | Ectopic varices显示文摘 | Majid Abdulrahman Almadi Abdulqader Almessabi Philip Wong Peter M. Ghali Alan Barkun | 2011 | Gastrointestinal Endoscopy2011，，2： | 3 |
| 7 | International Consensus Statement on surveillance and management of dysplasia in inflammatory bowel disease显示文摘 | Loren Laine Tonya Kaltenbach Alan Barkun Kenneth R. McQuaid Venkataraman Subramanian Roy Soetikno James E. East Francis A. Farraye Brian Feagan John Ioannidis Ralf Kiesslich Michael Krier Takayuki Matsumoto Robert P. McCabe Klaus M?nkemüller Robert Odze M | 2014 | Gastrointestinal Endoscopy2014，，： | 3 |
| 8 | Challenges in the management of acute peptic ulcer bleeding显示文摘 | James YW Lau Alan Barkun Dai-ming Fan Ernst J Kuipers Yun-sheng Yang Francis KL Chan | 2013 | The Lancet2013，，9882： | 3 |
| 9 | Is routine second-look endoscopy effective after endoscopic hemostasis in acute peptic ulcer bleeding? A meta-analysis显示文摘 | Sara El Ouali Alan N. Barkun Jonathan Wyse Joseph Romagnuolo Joseph J.Y. Sung Ian M. Gralnek Marc Bardou Myriam Martel | 2012 | Gastrointestinal Endoscopy2012，，2： | 2 |
| 10 | Medical research during the COVID-19 pandemic显示文摘The current pandemic of coronavirus disease 2019(COVID-19)which was first detected in Wuhan,China in December 2019 is caused by the novel coronavirus named severe acute respiratory syndrome coronavirus-2(SARS-CoV-2).The virus has quickly spread to a large number of countries leading to a great number of deaths.Unfortunately,till today there is no specific treatment or vaccination for SARS-CoV-2.Most of the suggested treatment medications are based on in vitro laboratory investigations,experimental animal models,or previous clinical experience in treating similar viruses such as SARS-CoV-1 or other retroviral infections.The running of any clinical trial during a pandemic is affected at multiple levels.Reasons for this include patient hesitancy or inability to continue investigative treatments due to self-isolation/quarantine,or limited access to public places(including hospitals).Additional barriers relate to health care professionals being committed to other critical tasks or quarantining themselves due to contact with COVID-19 positive patients.The best research approaches are those that adapt to such external unplanned obstacles.Ongoing clinical trials before COVID-19 pandemic have the potential for identifying important therapies in the long-term if they can be completed as planned.However,these clinical trials may require modifications due a pandemic such as this one to ensure the rights,safety,and wellbeing of participants as well as medical staff involved in the conduction of clinical trials.Clinical trials initiated during the pandemic must be time-efficient and flexible due to high contagiousness of severe acute respiratory syndrome coronavirus 2,the significant number of reported deaths,and time constraints needed to perform high quality clinical trials,enrolling adequate sample sizes.Collaboration between different countries as well as implementation of innovative clinical trial designs are essential to successfully complete such initiatives during the current pandemic.Studies looking at the long term sequalae of COVID-19 are also of importance as recent publications describe multi-organ involvement.Long term follow-up of COVID-19 survivors is thus also important to identify possible physical and mental health sequellae. | Khalid AlNaamani Siham AlSinani Alan N Barkun | 2020 | World Journal of Clinical Cases2020，8，15： | 2 |
| 11 | Pretransplantation α-Fetoprotein Slope and Milan Criteria: Strong Predictors of Hepatocellular Carcinoma Recurrence After Transplantation显示文摘 | Teodora C. Dumitra Sinziana Dumitra Peter P. Metrakos Jeffrey S. Barkun Prosanto Chaudhury Marc Deschênes Steven Paraskevas Mazen Hassanain Jean I. Tchervenkov | 2013 | Transplantation Journal2013，，1： | 2 |
| 12 | Efficacy of mycophenolate mofetil combined with very low-dose cyclosporine microemulsion in long-term liver-transplant patients with renal dysfunction显示文摘 | Cantarovich M Tzimas GN Barkun J | 2003 | Transplant2003，76，1： | 1 |
| 13 | Low dose octretide and tamoxifen in the treatment of the pancreas显示文摘 | Rosenberg L Barkun An Denis MH | 1995 | Cancer1995，75，： | 1 |
| 14 | Factors determining conversion tolaparotomy in laparotomy in patients undergoing laparoscopic cholecystectomy显示文摘 | Fried G M Barkun J S Sigman H H | 1994 | Am J Surg1994，167，1： | 1 |
| 15 | The Clavien-Dindo classification of surgical complications:five-year experience显示文摘 | Clavien P A Barkun J De Oliveira M L | | 0，，02： | 1 |
| 16 | Stress-related mucosal dis- ease in the critically ill patient 显示文摘 | Bardou M Quenot JP Barkun A | 2015 | Nat Rev Gastroenterol Hepatol2015，12，2： | 1 |
| 17 | Factors determining conversion to laparotomy in patients undergoing laparoscopic cholecystectomy显示文摘 | Fried GM Barkun JS Sigman HH | 1994 | Am J Surg1994，167，1： | 1 |
| 18 | Toxic megacolon complicating pseudomembranous enterocolitis显示文摘 | Dr. Judith L. Trudel M.D. M.Sc F.R.C.S.C. Marc Deschênes M.D. F.R.C.P.C. Serge Mayrand M.D. F.R.C.P.C. Alan N. Barkun M.D. F.R.C.P.C | 1995 | Diseases of the Colon & Rectum1995，，10： | 1 |
| 19 | Prokinetics in acute upper GI bleeding: a meta-analysis显示文摘 | Alan N. Barkun Marc Bardou Myriam Martel Ian M. Gralnek Joseph J.Y. Sung | 2010 | Gastrointestinal Endoscopy2010，，6： | 1 |
| 20 | Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding显示文摘 | Barkun A Bardou M Marshall JK | 2003 | Ann Intern Med2003，139，10： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员